Company intelligence / Profile preview

AMO Pharma Limited

Leeds, England, United Kingdomamo-pharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

AMO Pharma is advancing multiple clinical programs, with their lead candidate AMO-02 (tideglusib) progressing to Phase III for Type 1 myotonic dystrophy (DM1) following FDA discussions. Their previous Phase II/III REACH-CDM study in children and adolescents with congenital-onset DM1 showed the treatment was generally safe and well-tolerated.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

3 assets

tideglusib

2 more assets in the full pipeline.

Request access →

Partnerships

Ranedis Pharmaceuticals

Beyond the preview

Go deeper on AMO Pharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMO Pharma Limited.

Explore the full profile